Cresset Asset Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.78M | Buy |
9,415
+2,211
| +31% | +$416K | 0.01% | 703 |
|
|
2026
Q1 | $1.41M | Buy |
7,204
+940
| +15% | +$181K | 0.01% | 660 |
|
|
2025
Q4 | $1.15M | Buy |
6,264
+663
| +12% | +$116K | ﹤0.01% | 742 |
|
|
2025
Q3 | $859K | Buy |
5,601
+1,972
| +54% | +$298K | ﹤0.01% | 796 |
|
|
2025
Q2 | $507K | Sell |
3,629
-5,240
| -59% | -$734K | ﹤0.01% | 928 |
|
|
2025
Q1 | $1.3M | Sell |
8,869
-837
| -9% | -$121K | 0.01% | 679 |
|
|
2024
Q4 | $1.27M | Sell |
9,706
-41,617
| -81% | -$5.83M | 0.01% | 704 |
|
|
2024
Q3 | $8M | Buy |
51,323
+3,534
| +7% | +$570K | 0.03% | 360 |
|
|
2024
Q2 | $7.45M | Buy |
47,789
+20,282
| +74% | +$3.05M | 0.03% | 348 |
|
|
2024
Q1 | $3.73M | Buy |
27,507
+3,080
| +13% | +$408K | 0.02% | 433 |
|
|
2023
Q4 | $3.29M | Sell |
24,427
-2,705
| -10% | -$352K | 0.02% | 418 |
|
|
2023
Q3 | $3.67M | Buy |
27,132
+3,147
| +13% | +$430K | 0.01% | 392 |
|
|
2023
Q2 | $3.43M | Buy |
23,985
+21,152
| +747% | +$3.11M | ﹤0.01% | 500 |
|
|
2023
Q1 | $393K | Buy |
2,833
+23
| +0.8% | +$3.09K | 0.01% | 549 |
|
|
2022
Q4 | $282K | Sell |
2,810
-2,294
| -45% | -$288K | ﹤0.01% | 542 |
|
|
2022
Q3 | $560K | Sell |
5,104
-144
| -3% | -$18.3K | 0.01% | 476 |
|
|
2022
Q2 | $683K | Sell |
5,248
-1,645
| -24% | -$216K | 0.01% | 466 |
|
|
2022
Q1 | $913K | Sell |
6,893
-3,967
| -37% | -$476K | 0.01% | 432 |
|
|
2021
Q4 | $1.26M | Sell |
10,860
-2,948
| -21% | -$347K | 0.01% | 387 |
|
|
2021
Q3 | $1.66M | Buy |
13,808
+7,657
| +124% | +$891K | 0.02% | 262 |
|
|
2021
Q2 | $737K | Buy |
6,151
+139
| +2% | +$15.3K | 0.01% | 441 |
|
|
2021
Q1 | $598K | Buy |
6,012
+2,878
| +92% | +$289K | 0.01% | 430 |
|
|
2020
Q4 | $313K | Sell |
3,134
-370
| -11% | -$39.2K | 0.01% | 542 |
|
|
2020
Q3 | $384K | Buy |
3,504
+281
| +9% | +$31.3K | 0.01% | 435 |
|
|
2020
Q2 | $341K | Sell |
3,223
-165
| -5% | -$17K | 0.01% | 424 |
|
|
2020
Q1 | $303K | Buy |
3,388
+440
| +15% | +$41.4K | 0.01% | 386 |
|
|
2019
Q4 | $294K | Sell |
2,948
-1,135
| -28% | -$107K | 0.01% | 436 |
|
|
2019
Q3 | $364K | Buy |
+4,083
| New | +$354K | 0.01% | 327 |
|
|
2019
Q2 | – | Sell |
-3,319
| Closed | -$268K | – | 586 |
|
|
2019
Q1 | $268K | Buy |
3,319
+1,508
| +83% | +$119K | 0.01% | 294 |
|
|
2018
Q4 | $138K | Buy |
+1,811
| New | +$141K | 0.01% | 266 |
|
Other funds holding AZN
EP
IA
Cresset Asset Management's AZN Position: Q2 2026 in Review
Cresset Asset Management increased its AstraZeneca (AZN) stake by 31% in Q2 2026, buying an estimated $416K and bringing the position to 9,415 shares worth $1.78M. The position accounts for 0.01% of the portfolio, ranked #703.
Cresset Asset Management first reported a position in AZN in Q4 2018 and has held it in 30 quarters since. The position peaked at $8M in Q3 2024. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Cresset Asset Management held 9,415 shares of AstraZeneca worth $1.78M as of Q2 2026.
- Cresset Asset Management bought 2,211 AstraZeneca shares in Q2 2026, an estimated $416K.
- AstraZeneca made up 0.01% of Cresset Asset Management's portfolio in Q2 2026, its #703 holding.
- Cresset Asset Management first reported a position in AstraZeneca in Q4 2018 and has held it in 30 quarters since.
- Cresset Asset Management's AstraZeneca position peaked at $8M in Q3 2024.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.